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Abstract  
Leptin, a peptide hormone secreted by adipocytes in proportion of the amount 
of energy stored in fat, plays a central role in regulating human energy 
homeostasis, controlling food intake, reproductive and immune functions. As a 
cytokine, leptin can affect thymic homeostasis and the secretion of acute-phase 
reactants such as interleukin-1 and tumour-necrosis factor (1). Decreased levels 
of leptin, also known as hypoleptinemia, signal to the brain a state of energy 
deprivation. Hypoleptinemia can be a congenital or acquired condition, and is 
associated with alterations of several neuroendocrine axes, including the 
hypothalamic-pituitary-gonadal, -thyroid, -growth hormone, and -adrenal axes 
(2). A model of acquired chronic hypoleptinemia induced by negative energy 
balance is the hypothalamic amenorrhea (HA), previously it has been 
demonstrated that hypoleptinemia underlies the dysfunction of neuroendocrine 
axes and bone metabolism associated with HA (3). In uncontrolled human 
studies, low leptin levels are associated with impaired immune responses and 
reduced T cell counts but effects of leptin replacement on the adaptive immune 
system have not yet been reported in the context of randomized controlled 
studies and/or in conditions of chronic, acquired leptin deficiency. To address 
these questions, we performed the first randomized, double-blinded, placebo-
controlled trial of recombinant methionyl-human-leptin (metreleptin) 
administration in replacement doses over 36 weeks in women with HA. 
Metreleptin restored both CD4
+ 
T cell counts and their in vitro proliferative 
responses, these changes were accompanied by a transcriptional signature 
where relevant genes of cell survival and hormonal response were up-regulated 
and apoptosis genes were down-regulated in circulating immune cells. We also 
observed that signaling pathways of cell growth/survival/proliferation were 
directly activated by acute in vivo metreleptin administration in subjects with 
both chronic hypoleptinemia and normoleptinemic lean female subjects. These 
data show that metreleptin administration, in doses that normalize circulating 
leptin levels, induce transcriptional changes, activate intracellular signaling 
pathways and restore CD4
+ 
T cell counts. Thus, metreleptin may prove to be a 
safe and effective therapy for selective CD4
+
 T cell immune-reconstitution in 
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hypoleptinemic states associated with cachexia such as tuberculosis and HIV 
infection in which CD4
+
 T cells are reduced. 
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Introduction 
Leptin as an immunoendocrine mediator  
Leptin circulates as a nonglycosylated protein of relative molecular mass 16 
kDa in mouse and human plasma. Leptin is a peptide coded by the obese (ob) 
gene, which is located on human chromosome 7 and on mouse chromosome 6, 
and secreted with circadian rhythm mainly by adipocytes. The plasma levels of 
leptin are highly correlated with adipose tissue mass, indeed its levels are 
increased in obese humans and in several genetic forms of rodent obesity (4). 
Mutations of the ob gene are associated with many of the abnormalities seen in 
starved animals, such as hyperphagia, reduced energy expenditure, decreased 
immune function and other reproductive, neuroendocrine, and metabolic 
dysfunctions (5). Leptin initially described as an anti-obesity hormone, has 
subsequently been shown also to influence basal metabolism, hematopoiesis, 
thermogenesis, reproduction, and angiogenesis, regulating the balance between 
food intake and energy expenditure, signaling to the brain the changes in stored 
energy. Leptin mainly produced by the adipose tissue in proportion to the body 
fat mass and, at lower levels by other tissue, such as placenta, stomach and 
skeletal muscle; its receptor (Ob-R) was first isolated from mouse choroid 
plexus by expressing cloning. It was identified as a member of the cytokine 
family of receptors and binds leptin with nanomolar affinity (6). There are five 
spliced form of Ob-R: Ob-Ra, Ob-Rb, Ob-Rc, Ob-Rd and Ob-Re; four of the 
five have transmembrane domains, but only Ob-Rb, known as Ob-RL, is the 
isoform with long cytoplasm region containing several motif required for 
signal transduction, through Jak-Stat pathway (7). Mutations in Ob-R lead to 
massive obesity in db mice with phenotype identical to that of ob mice; most of 
the mutations affect all of the splice forms. Ob-Rb is normally expressed in 
hypothalamic neurons and in other cell type including T cells and vascular 
endothelial cells (8-10). Leptin induces activation of the transcription factor 
Stat3, and increases the expression of fos and other genes in the hypothalamus 
of mice (11). Leptin gene expression is regulated by several factors, including 
hormones such as insulin, glucocorticoids, and sex hormones. Insulin 
stimulates leptin secretion during feeding, and a decrease in insulin levels 
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anticipates a fall in leptin during starvation. Glucocorticoids also operate 
synergistically with insulin in the secretion of leptin from cultured adipocytes, 
although an inverse relationship between leptin and glucocorticoids is 
generally observed (7). Finally, leptin expression is inhibited by testosterone, 
increased by ovarian sex steroids, and directly influences the hypothalamic-
pituitary-adrenal axis, the reproductive system, hematopoiesis, and 
angiogenesis. A series of studies has linked the immune and neuroendocrine 
systems, indeed mediators that are common to neuroendocrine and immune 
systems can modulate inflammation through the hypothalamus-pituitary-
adrenal axis (12, 13). In the immune system, leptin, together with C-reactive 
protein (CRP), IL-1, and IL-6, can act as an early acute-phase reactant, 
produced at high levels during inflammation, sepsis, and fever, and it can be 
induced by other inflammatory mediators such as TNF and IL-1 (14, 15) 
(Figure 1). However, although these findings have been demonstrated in 
several systems, other studies have not found increased leptin in inflammatory 
conditions in humans, including acute experimental endotoxaemia, newborn 
sepsis, and HIV infection and during anti-inflammatory therapy (16-18). The 
neuroendocrine role of leptin is most evident in conditions such as fasting, 
during which the production of leptin by adipose tissue is markedly reduced, or 
in relation to the effects of sex hormones on its production, indeed testosterone 
reduces the secretion of leptin, whereas estrogens increase its production. In 
this context the link between leptin and sex hormones is also indicated by the 
marked gender dimorphism, manifested by a higher serum concentration in 
females than in males with similar body-fat mass (7). Since there is a 
functional connection and anatomical contiguity between adipocytes and 
lymphoid cells, it is not surprising that leptin has effects on both the 
neuroendocrine and immune systems (Figure 1). Morphologically, 
aggregations of lymphoid tissue, including the lymph nodes, thymus, and bone 
marrow, are associated with adipose tissue (19). Fat deposits do not simply 
have a structural, metabolic, and heat-insulating function but also provide a 
microenvironment that helps the immune system to sustain immune responses. 
In particular, lymphoid and adipose tissues interact locally through common 
mediators known as adipokines, adipocyte-derived molecules that bridge 
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metabolism, and immune homeostasis, these molecules include leptin, 
adiponectin, chemokines, and other proinflammatory cytokines. 
 
 
 
 
 
 
 
 
Figure1. The neuroendocrine effects of leptin. 
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Leptin in innate and adaptive immunity  
The functional long form of the leptin receptor (LepRb) is expressed in the 
hypothalamus where it regulates energy homeostasis and neuroendocrine 
function; it is also expressed in cells of the innate and adaptive immune system 
where leptin exerts key regulatory functions (1). On the basis of studies in 
rodents as well as observational and uncontrolled studies in a limited number 
of human subjects with congenital leptin deficiency, leptin has also been 
proposed to act as a signal that conveys information on energy availability to 
the immune system. The immune system, similar to the neuroendocrine 
system, requires an adequate supply of energy for optimal functioning (8, 20). 
Evidence of leptin’s importance can be found in animal studies where mice that 
lack either leptin or LepRb show defects in cell-mediated pro-inflammatory T-
helper-1 (Th1)-type immune responses (8, 20). Human with congenital leptin 
deficiency show an increased risk for infection-related deaths during childhood 
and have reduced lymphocyte subpopulation numbers. Particularly, the T cell 
CD4
+
 fraction and the T-cell-receptor (TCR)-specific proliferative responses 
are reduced when compared with the general population. Indeed, recent 
evidence has demonstrated in children with congenital leptin deficiency ,that a 
direct effect of recombinant methionyl-human leptin (metreleptin) replacement 
to correct immunophenotypic changes, specifically increasing circulating  
naive CD4
+
CD45RA
+
 T-cell numbers and reversing impaired T-cell 
proliferation/cytokine release in response to TCR stimulation (21). Studies in 
mice have shown that the effect of leptin on the immune system is direct and 
indirect, via modulation of central or peripheral pathways. Leptin affects both 
innate and adaptive immunity, indeed in innate immunity it seems to promote 
activation of and phagocytosis by monocytes/macrophages and their secretion 
of leukotriene B4 (LTB4), cyclo-oxigenase 2 (COX2), nitric oxide and pro-
inflammatory cytokines (22-24) (Figure 2). The products of the inducible form 
of COX2—PGs and LTs (also known as eicosanoids)—as well as NO are 
involved in the regulation of inflammation, chemotaxis, and cytokine 
production and therefore, markedly impact the immune response.  Moreover, 
leptin can induce chemotaxis of neutrophilis and the release of oxygen radicals 
(25, 26). These mediators can be particularly harmful to cells, as they can 
 
7 
 
denature proteins and damage membrane lipids (by peroxidation of unsaturated 
fatty acids), carbohydrates, and nucleic acids. At least in human neutrophils, 
leptin seems to mediate its effects through an indirect mechanism, probably 
involving the release of TNF from monocytes (25, 26). Leptin also affects 
natural killer (NK)-cell development and activation both in vitro and in vivo 
(27, 28) (Figure 2). As NK cells express OBRb, and db/db mice have a deficit 
of NK cells resulting from abnormal NK cell development, it is possible that 
leptin might influence the development/maintenance of a normal, peripheral 
NK cell pool. Indeed, an important role of OBRb in NK cell physiology is 
indicated by the ability of OBRb to influence NK cell cytotoxicity through 
direct activation of STAT3 and the transcription of genes encoding IL-2 and 
perforin. In addition to above mentioned activity, leptin can stimulate the 
production of growth hormone by peripheral-blood mononuclear cells 
(PBMCs) through protein kinase C (PKC) and nitric oxide-dependent 
pathways. This last effect might be important in immune homeostasis, given 
the fact that this cytokine-like hormone has marked influences on immune 
responses by controlling the survival and proliferation of immune cells (24). 
Instead regard the effects of leptin on adaptive immune responses, have been 
investigated extensively on human CD4
+
 T cells (Figure 2). Addition of 
physiological concentrations of leptin to a MLR induces a dose-dependent 
increase in CD4
+
 T cell proliferation (8). However, leptin has different effects 
on proliferation and cytokine production by human naive (CD45RA
+
) and 
memory (CD45RO
+
) CD4+ T cells (both of which express OBRb). Leptin 
promotes proliferation and IL-2 secretion by naive T cells, whereas it 
minimally affects the proliferation of memory cells (on which it promotes a 
bias toward Th1 cell responses). Another important role of leptin in adaptive 
immunity is highlighted by the observation that leptin deficiency in ob/ob mice 
is associated with immunosuppression and thymic atrophy—a finding similar 
to that observed in acute starvation (8). Acute caloric deprivation causes a 
rapid decrease of serum leptin concentration accompanied by reduced delayed-
type hypersensitivity (DTH) responses and thymic atrophy, which are 
reversible with administration of leptin (8, 29, 30). The thymic atrophy in 
ob/ob mice (or wild-type, starved animals) affects the cortex of the thymus, in 
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which most CD4
+
CD8
+
 T cells are found, and leptin replacement reduces the 
rate of apoptosis of such cells (29). Despite the evidence of direct effects of 
leptin on immune responses in vitro, a major problem remains whether leptin 
can influence immune responses in vivo. This task is particularly difficult, 
because of the complexity of the network of interactions that link leptin to 
several endocrine pathways. It is notable that T cells are sensitive to the supply 
of cellular nutrients, such as glucose (31), as they do not have glycogen stores 
and therefore, depend on the import of extracellular glucose to meet their 
metabolic needs (32). By stimulating glucose uptake through ERK1/ERK2- 
and PI-3K-dependent pathways, leptin might help to restore the impaired T cell 
function caused by starvation (29). In this context, it is worth mentioning that 
other long-chain helical cytokines similar to leptin (such as IL-3, IL-7, and IL-
15) are important in promoting the uptake and metabolism of glucose (32). 
 
Figure 2. Schematic representation of the effects of leptin on both innate and adaptive 
immunity. 
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Leptin in hypothalamic amenorrhea 
 
In 1994, the discovery of leptin has changed the perspective of adipose tissue 
from that of an inert energy store to a true endocrine organ that secretes 
metabolically active hormones (33). Several studies in mice (34) and human 
(35) have shown that leptin has a role in the neuroendocrine adaption to 
starvation, which includes changes in hormone concentrations that probably 
have a protective effect. These findings are clinically relevant for common 
disease states associated with low leptin concentrations and neuroendocrine 
abnormalities (energy-deficient states such as exercise-induced amenorrhoea, 
non-athletic forms of hypothalamic amenorrhea and anorexia nervosa). 
Hypothalamic amenorrhea (HA), either organic or functional, (36) is 
characterized by the absence of menstrual cycle, low or normal levels of 
gonadotropins. Functional hypothalamic amenorrhea occurs when a relative 
energy deficit (owing to weight loss, excessive exercise, or eating disorders) 
disrupts the secretion of hypothalamic gonadotropin-releasing hormone 
(GnRH) and other neuroendocrine axes ( 37, 38). Leptin, a hormone that 
regulates the energy homeostasis, is a prime candidate. There are leptin 
receptors in the hypothalamus and these found in both the area associated with 
eating behaviour and energy balance and the area concerned with reproduction 
regulation (arcuate, ventro-medialis and paraventricular nucleus) (39). The 
long isoform, expressed abundantly in hypothalamus, activates mainly the 
Janus kinase signal transducer and activator of transcription system to change 
the expression of hypothalamic neuropeptides and thus regulate energy 
homeostasis (40). In the hypothalamus the target of leptin is neuropeptide-Y 
(NPY) and pro-opiomelanocortin (POMC), both involved in regulation of body 
weight and reproduction (41). An inadequate leptin production as occurs in 
women with nutritional amenorrhea, could induce hypercortisolism through an 
increase in corticotrophin-releasing hormone (CRH) secretion and adrenergic 
activation; leptin acts directly or indirectly on hypothalamic receptors, by 
affecting NPY or POMCS ( 41). Evidence from in vitro studies and models of 
leptin deficiency in animals and man, suggest that leptin has an important role 
in reproduction and regulation of the hypothalamic-pituitary-gonadal axis, 
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indeed in vitro, leptin stimulates gonadotropin-releasing hormone pulsatility 
and release (42). Leptin-deficient ob/ob mice are morbidly obese but also 
sterile, and leptin treatment is able to correct the sterility of these mice (43, 44). 
The hypothalamic menorrhea condition arises when impaired secretion of 
gonadotropin-releasing hormone leads to low or normal gonadotropin 
concentrations, low oestrogen concentrations and subsequently the absence of 
menstrual cycle (37). This condition can be deemed to represent a regression to 
a prepubertal or peripubertal pattern of gonadotropin secretion. Several 
evidence has shown that amenorrheic female athletes have lower serum leptin 
concentrations than weigh-matched controls, associated with neuroendocrine 
abnormalities, supporting the idea that leptin plays an important role in 
reproductive and neuroendocrine function associated with this disorder. Studies 
conducted by Mantzoros have shown that the administration of recombinant 
methionyl human leptin (r-metHuLeptin) at replacement doses to woman with 
hypothalamic amenorrhea, improved ovarian parameters, increased levels of 
LH, estradiol, IGF-1 and thyroid hormone (45), suggesting that leptin is a 
peripheral signal of adequate energy stores necessary for normal reproductive 
and neuroendocrine functions and leptin replacement could became a potential 
new therapeutic option (33). 
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Aim of study 
 
During the last decade, there has been a growing understanding of how host 
nutritional status and metabolism can affect the immune response. In this 
context, studies in vitro and in animal models suggest that leptin, the prototype 
adipose tissue derived cytokine, is able to participate in a wide range of 
biological functions that include—in addition to its function as an adipostat—
glucose metabolism and CD4
+
 T lymphocyte proliferation, cytokine secretion 
and apoptosis, underlying the link between immune function/homeostasis, 
metabolism and nutritional state. The aim of the present study was to 
characterize the role of leptin on CD4
+
 T cell homeostasis in a state of acquired 
leptin deficiency, such as HA, a condition in which adipose tissue is 
particularly reduced and consequently serum leptin concentrations are also 
chronically lower. This is the first randomized, placebo-controlled trial on the 
effects on immune function of rrecombinant methionyl-human-leptin 
(metreleptin) administration in humans over a period of 36 weeks. We report 
for the first time that metreleptin in replacement doses restored the number and 
function of CD4
+
 T cells and their proliferative potential, which was impaired 
in hypoleptinemic women. We also assessed the modulation of gene expression 
in T cells from these subjects at various time points during metreleptin 
treatment and we observed that metreleptin induced the up-regulation of genes 
involved in cell survival and in hormonal response while induced down-
regulation of cell death/apoptosis genes. Our data have relevance in 
hypoleptinemic states associated with negative energy balance, such as 
recurrent infections associated with reduced T cell counts, immunodeficiencies 
such as HIV and Tuberculosis all of which are very frequently associated with 
low body weight and decreased adipocyte mass. Our findings might pave the 
way for clinical researchers to translate our findings to new therapeutic options 
that could selectively affect the crosstalk between immune system and 
metabolic status through leptin administration.   
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Materials and Methods  
Placebo-controlled trial of metreleptin replacement in women with HA 
 Eligible subjects were women between 18 and 35 years old with secondary 
HA, defined by an absence of menstrual cycles for 6 months or more, in the 
setting of strenuous exercise or negative relative energy balance. All had 
normal weight (within 15% of ideal body weight for six months or more) that 
had not fluctuated more than +/- 5 lb over the last 6 months. All subjects had 
baseline serum leptin levels of less than 5 ng/ml, but were otherwise healthy, 
with an absence of significant coexisting medical conditions and psychiatric 
diseases, including depression or past/active eating disorders. This was 
determined using a screening questionnaire, physical examination, and routine 
blood tests. Other causes of absent menstrual cycles were excluded, including 
hypothyroidism or hyperthyroidism, polycystic ovarian syndrome, 
hyperprolactinemia, Cushing’s syndrome, congenital adrenal hyperplasia, or 
primary ovarian failure. None of the subjects had been taking medications 
known to affect neuroendocrine, immunological or bone density 
measurements, including glucocorticoids, anti-seizure medications, thyroid 
hormones, and estrogens. Also excluded were women who were breastfeeding, 
pregnant, or planning pregnancy within one year, and those with a known 
history of hypersensitivity to E. coli derived proteins. Because  the effects of 
metreleptin on the developing fetus are not known, all subjects were required 
to use double barrier methods of contraception (diaphragm with intravaginal 
spermicide, cervical cap, male or female condom with spermicide). All 
participants were tested for pregnancy at screening and at all subsequent visits.  
 
Study design: placebo-controlled, randomized trial of metreleptin 
replacement in women with HA  
This protocol was approved by the Institutional Review Board of Beth Israel 
Deaconess Medical Center, and clinical quality human recombinant leptin 
(metreleptin, A-100, formerly known as met-Hu-leptin; phase II clinical trial) 
was provided by Amylin Pharmaceuticals. Metreleptin was administered in the 
context of an Investigator Initiated Study protocol and under an Investigational 
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New Drug application by CSM to the Food and Drug Administration. Twenty 
women were enrolled and provided written informed consent to participate in a 
randomized, double-blind, placebo-controlled trial. Fourteen of these subjects 
were eventually studied for immune phenotype and function outcomes. Data 
from all twenty subjects was utilized in the microarray analysis. Subjects were 
randomized in a 1:1 fashion to receive either metreleptin or placebo, for a 
period of 36 weeks in the form of a self-administered daily subcutaneous 
injection (given between 7pm and 11pm). Eight subjects were randomized to 
receive metreleptin and six placebo. The initial dose of metreleptin was 
0.08mg/kg, aiming at achieving a concentration of endogenous leptin within 
the normal range. If by week 12 participants had no clinical response i.e. had 
not begun menstruating, their doses were increased to 0.12 mg/kg and 
continued on this dose until week 36. Weight was monitored at monthly visits, 
and metreleptin doses were adjusted accordingly. Metreleptin doses were 
reduced by 0.04 mg/kg if the participant lost >5% of baseline weight.  
Participants with weight loss of > 8% of their baseline weight or found to be < 
80% of ideal body weight were withdrawn from the study. All subjects also 
received the current standard of care for HA, including calcium (600 mg twice 
a day) and vitamin D (400 international units daily) supplementation. Fasting 
blood samples were obtained at visits to our General Clinical Research Center 
(GCRC) at baseline and every four weeks. In all phases of the study, 
heparinized blood samples were collected at the baseline visit and every 12 
weeks thereafter and were shipped to Naples, Italy, by express courier to be 
processed within 48h for immune assays. Processing of PBMCs within this 
time frame assures their viability, according to standard immunology procedure 
and verified by our extensive studies in healthy controls and leptin-deficient 
subjects using a similar protocol (46). PBMCs were also collected at these time 
points at C.S.M’s BIDMC laboratory using the same standard immunology 
procedure as that used in Italy. RNA for microarray analysis was isolated from 
PBMCs at the BIDMC Genomics and Proteomics Center using the 
manufacturer’s protocol for Trizol Reagent (Invitrogen, Grand Island, NY).  
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Study design: healthy controls 
In this study we additionally included 13 healthy volunteer donors. The healthy 
controls were matched for age, BMI and leptin levels with HA patients at 
baseline (Table 1). None of these had a history of endocrine disease, 
autoimmune disorders or infection. The study was approved by the institutional 
ethics committee and all individuals gave written informed consent. The 
experimental procedures for the immunephenotype analysis of peripheral blood 
and lymphocyte cultures and stimulation after isolation of human PBMCs were 
the same of those described for the hypothalamic amenorrhea patients.  
 
Acute Metreleptin Signaling study of PBMCs in vivo and CD4
+ 
cells in 
vitro 
Normal, healthy lean volunteers were recruited from the community and 
screened at the Clinical Research Center (CRC) at BIDMC. Subjects were 
excluded if they had a history of any illness, other than obesity, that may affect 
insulin sensitivity, use of medications that are known to influence glucose 
metabolism, history of anaphylaxis or anaphylactoid-like reactions or a known 
hypersensitivity to E. coli-derived proteins or anesthetic agents such as 
Lidocaine or Novocaine. All subjects provided written informed consent to 
participate and the study was approved by the institutional review board at 
BIDMC. Subjects were provided with take-home meals and consumed an 
isocaloric diet, specifically designed for each subject, for 48 hours prior to their 
main study visit to ensure stable dietary intake. On the morning of the main 
study visit, subjects attended the CRC after a 12 hour fast. For an acute in vivo 
metreleptin signaling study, we performed experiments with PBMCs before 
and after a bolus of metreleptin (0.01 mg/kg body weight for 20 min) or 
placebo (10 cc of normal saline for 20 min) injection. Either metreleptin or 
placebo was administered to 3 lean females (BMI 22.21±0.32 kg/m
2
), by slow 
intravenous injection over one minute. In another group of lean subjects, 
human CD4
+
 T cells were purified from PBMCs by magnetic cell separation 
with Dynabeads CD4
+
 T cell Kit (Invitrogen). Soon after isolation, CD4 cells 
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were 95-98% pure as verified by FACS analysis. Isolated CD4 cells were used 
for acute in vitro molecular signaling studies. 
Immunephenotype  
Immunophenotypic analysis of peripheral blood was performed with an EPICS 
XL flow cytometer (Beckman Coulter). Triple combinations of different anti-
human mAbs, e.g., FITC- and phycoerythrin (PE)-anti-CD3, PE- and PC-5-
anti-CD4, PC5-anti-CD8, PE-anti-CD16, PC5-anti-CD19, PE-anti-CD25, 
FITC-anti-CD45, and PE-anti-CD56 (Coulter Immunotech), were used for 
immunofluorescence staining.  
 
Lymphocyte cultures and stimulation  
Human PBMCs were isolated by stratifying 15 mL of whole blood on 5 mL of 
Ficoll-Paque PREMIUM (GE Healthcare) and centrifuging the solution at 1.2 x 
g for 20 minutes. Next, the lymphocyte layer was removed and washed twice 
by resuspending the pellet with 40 ml of serum free RMPI medium and a 
centrifugation of 1700 rpm for 5 minutes, at RT. Viability of cells was verified 
at 85-95% by using tryphan blue staining and annexin-5 binding during flow 
cytometry, and serum glucose levels were measured as a marker of metabolic 
activity, and T cells were cultured in medium supplemented with 5% (vol/vol) 
autologous subject serum. T cell cultures were performed in triplicate in 96-
well round-bottom plates. PBMCs (2 × 10
5
 per well) were stimulated in 
parallel with OKT3, 0.1 g/ml (Ortho); phytohemagglutinin, 2 g/ml (Sigma); 
phorbol 12-myristate 13-acetate, 0.01 M and ionomicin, 0.5 M (Sigma); and 
purified protein derivative (PPD) 10 g/ml (Northern Serum Institut) stimuli. 
Stimulated PBMCs were maintained for 72h in culture, and H3 thymidine was 
added (0.5Ci/well) over the last 12h. Cells were harvested on glass-fiber 
filters using a 96-well cell harvester (Tomtec Inc.), and counted in a 1205 
Betaplate liquid scintillation counter (Wallac). Results are expressed as mean 
(SD) counts per minute from triplicate cultures. 
 
 
16 
 
Cytokines and hormonal measurements  
Human obesity kit (Bender Medsystems GmbH) was used for quantitative 
detection of soluble MPO, ICAM-1, CD40L, TNF-R, MCP1 and OPG by flow 
cytometry (FACSCanto-BD) according to manufacturer’s instructions. Data 
were analyzed using FlowCytomix Pro 2.2 Software (Bender Medsystems 
GmbH). For leptin, IL-2, IL-7, IL-15, and leptin receptor measurements 
commercially available ELISA kits from R&D Systems, were utilized as 
previously described. The following hormone levels were measured using 
immunoassays: cortisol, IGF1, insulin and ACTH (Immulite; Siemens 
Healthcare Diagnostics). Serum leptin and free leptin were measured by RIA 
(Millipore) with a sensitivity of 0.5 ng/mL, intraassay coefficient of variability 
(CV) of 3.4–8.9%, and interassay CV of 3.0–6.2%.  
 
Levels of serum anti-metreleptin antibodies and their functional activity  
Levels of serum anti-metreleptin antibodies were determined with an in-house 
ELISA. In brief, 50 L metreleptin at a final concentration of 10 g/mL in 
PBS, pH 7.4, was plate-bound to a 96-well ELISA plate (PBI International 
SpA). After 16 h at 4°C, the plates were extensively washed with PBS-0.05% 
Tween 20, blocked with 200 L PBS/10% FCS for 2 h, and repeatedly washed. 
Diluted sera in PBS-0.05% Tween 20/10% FCS (from 1/10 to 1/1,000) were 
added at 100 L/well and incubated for 4 h at room temperature. After five 
washes, goat anti-human polyvalent immunoglobulins, such as alkaline 
phosphatase–conjugated antibodies (Sigma-Aldrich), were added at a 
concentration of 100 L/well for 1 h. The reaction was developed with Sigma-
Fast p-nitrophenyl phosphate and alkaline phosphatise substrate (PNPP) 
(Sigma-Aldrich) and read after 30 min at 405 nm in an ELISA plate-reader 
(Bio-Rad Laboratories). Standard curves of antileptin antibodies were 
developed in each assay using an antileptin monoclonal antibody (mAb) 
generated in our laboratory (mAb 971212). Quantification of optical density 
values was performed after extrapolation from standard curves of known 
concentration of antileptin antibodies. The functional activity of antileptin 
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antibodies was assessed with the human leptin-receptor (hLepR)-transfected 
BAF3 cell line, provided by Dr. Arieh Gertler (The Hebrew University). In 
brief, because hLepR+BAF3 cell proliferation is leptin dependent, 
hLepR+BAF3 cells were cultured in flat-bottom 96-well microtiter plates 
(Becton-Dickinson Falcon) at a density of 5x10
3
 cells/well in a total volume of 
100 L RPMI-1640 medium supplemented with 2% FCS (Hyclone-Pierce; 
Thermo Fisher Scientific), 2 mmol/L L-glutamine, 100 units/mL penicillin, and 
100 g/mL streptomycin (Life Technologies). Cells were cultured at 37°C in 
100% humidity and 5% CO2 in the presence of increasing doses of metreleptin 
ranging from 0.01 to 10 ng/mL. Purified IgGs from sera of metreleptin-treated 
subjects, placebo–treated subjects, and healthy controls were added to cells in 
all the different conditions at a final concentration of 50 g/mL. After 48 h, 
[
3
H] thymidine (0.5 Ci/well) (Perkin-Elmer) was added to the cultures, and 
cells were harvested after 12h. Radioactivity was measured with a -cell plate 
scintillation counter (Wallac). As standard of leptin neutralization, anti-human 
leptin mAb 971212 was used at increasing concentrations usually from 0.1 to 
25 g/mL. We also assessed at the biochemical level the capacity of antileptin 
IgGs, isolated from leptin or placebo-treated subjects and healthy controls, to 
affect LepR signaling in BAF3 cells. In brief, hLepR+BAF3 cells were 
incubated for 1 h at 37°C with recombinant leptin at 2 ng/mL in the presence or 
absence of IgGs (50 g/mL) purified from leptin- or placebo-treated subjects 
and healthy controls. After a 1-h incubation, cell lysates were generated to 
perform Western blotting analyses for STAT3 phosphorylation as a readout of 
LepR signaling. 
 
Protein extraction and western blotting  
For total cell extracts, collected samples were suspended in a lysis buffer 
containing 20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 5 mM ethylene diamine 
tetra acetic acid (EDTA), 0.1 mM phenylmethyl-sulfonyl fluoride (PMSF), 
0.05% aprotinin, and 0.1% Igepal and then incubated for 30 min at 4C. The 
suspension was centrifuged for 25 min at 12,000 rpm and the supernatant was 
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saved as the total extract. For Western Blotting, proteins were loaded in each 
lane. After SDS-polyacrylamide gel electrophoresis, proteins were blotted onto 
nitrocellulose membranes
 
(Schleicher & Schuell). The membranes were 
blocked for 1hr in TBS containing 5% nonfat dry milk and 0.1% Tween 20. 
Incubation with primary antibodies was performed in TBS containing 5% 
nonfat dry milk for overnight and then incubated with horseradish
 
peroxidase 
secondary antibodies for two hour. After incubation with antibodies, 
membranes were washed with TBS containing 0.1% Tween-20. Enhanced 
chemiluminescence was used for detection. The antibodies used were the 
following: anti-STAT3, anti-phospho-STAT3 (Y705), anti-mTOR, anti-
phospo-mTOR, anti-SHP2, anti-phospho-SHP2 (Cell Signaling Technology), 
anti-ERK, anti-phospho-ERK, anti AMPK, anti-phospho-AMPK, anti-AKT, 
anti-phospho-AKT (Santa Cruz). Measurement of signal intensity on 
nitrocellulose membranes
 
after Western Blotting with various antibodies was 
performed using Image J processing and analysis software 
(http://rsbweb.nih.gov/ij/). 
 
Microarray analyses  
Total RNA was isolated from PBMCs using the manufacturer’s protocol for 
Trizol Reagent (Invitrogen) and further purified using RNAeasy spin columns 
(Qiagen). RNA concentration and purity were determined from 260nm/280 nm 
absorbances. RNA integrity was determined using the Agilent 2100 BioChip 
(Agilent Technologies). The RNA was then subjected to a single amplification 
run, labeled with biotin nucleotides, digested into proper size fragments, and 
hybridized to the HT-HG-U133A and HT-HG-U133B gene microarrays 
(Affymetrix) following a standard protocol established by the manufacturer. 
Hybridized chips were reacted with FITC-avidin and raw fluorescence 
intensities were read with a laser scanner. Affymetrix GeneChip raw data (CEL 
files) were imported into R v. 2.13 and analyzed with the bioinformatics 
facilities present in the BioConductor packages (47). Data was quality checked 
with the BioConductor packages affyPLM and affy (48). Subsequently, the 
data was re-annotated according to the updated information present in the 
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NCBI Entrez Gene database (brainarray website 
http://brainarray.mbni.med.umich.edu/Brainarray/Database/CustomCDF/14.1.0
/entrezg.asp) and preprocessed by the RMA algorithm (49). The quality 
checked, re-annotated and preprocessed gene expression data were screened for 
differentially expressed genes by a linear model including the interaction of the 
treatment-by-time and the subject (pairing) terms (Y ~ treatment * time + 
subject + error) followed by moderated t-test for the pairwise comparisons of 
interest. Genes with nominal p-value < 0.01 were considered to be significantly 
differentially expressed. The lists of differentially expressed genes were then 
searched for over-represented biological themes by the DAVID annotation 
software with the default parameters (50). The microarray data used in this 
study is available at NCBI Gene Expression Omnibus (GEO) database under 
the accession number: GSE36990 (see site:  
 http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=rtmtdyekqooksxa&acc
=GSE36990). 
Real-Time PCR Validation 
Differentially expressed genes in microarray analyses were verified by real-
time PCR using ABI7500FAST (Applied Biosystems) with a 20-μL reaction 
volume consisting of cDNA transcripts, primer pairs, and SYBR Green PCR 
Master Mix (Applied Biosystems). Quantifications were normalized to 18S in 
each reaction. The sequences for the primers are listed in Table 5. 
 
Statistics  
Differences in baseline characteristics between HA and control subjects were 
calculated using unpaired t tests. Where data was not normally distributed, we 
used Nonparametric Mann-Whitney U tests. The statistical software used was 
GraphPad InStat3 version 3.0. For the acute in vivo metreleptin signaling study, 
data were analyzed student t-test and/or one-way ANOVA followed by post-
hoc test for multiple comparisons. Analyses were carried out using SPSS 
(version 11.5, SPSS). 
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Results 
Baseline characteristics of the leptin and placebo treated subjects and healthy 
controls are presented in Table 1. There was no significant difference between 
the HA groups and normal females as controls with regards to age, weight, 
BMI, and leptin levels.  
 
 
 
 
 
 
Table 1. Baseline characteristics of all enrolled subjects. No significant differences were 
found among the three groups with regards to age, body-mass index and leptin levels. 
 
Efficacy of metreleptin to increase CD4
+
 T cell number in HA subjects  
We first studied whether leptin treatment could affect the immune phenotype 
of HA subjects. We initially compared the total number of lymphocytes and 
several sub-populations between the HA subjects (n=14) and normal matched 
control subjects (n=13) at baseline. The HA subjects had a significantly lower 
number of total lymphocytes, B, and NK cells. The difference in the 
populations of CD4 and CD8 T cells followed the same trend but the difference 
was not statistically significant (Figure 1). After 36 weeks of metreleptin 
administration in replacement doses the lymphocyte sub-populations of  CD3
+
 
and CD4
+
 cells increased in terms of  fold change (calculated as the 
difference between week of the treatment and baseline) (p < 0.05) and in terms 
of absolute cell number compared with controls (Figures 2 and 1, respectively). 
B and NK cell populations did not change significantly. Within the CD3
+
 T cell 
population, we observed an increase in both the naïve and memory CD4
+
 cells, 
 
Characteristics 
Baseline in Subjects  
Receiving Placebo 
             (n=6)    
 
Baseline in Subjects  
Receiving metreLeptin  
             (n=8) 
 
 
Healthy controls  
            (n=13) 
 
 mean±SD          range  
 
 
mean±SD          range  
 
 
mean±SD          range  
 
 
Age (yr) 
 
25 ± 4.1            18-31 
 
 
26 ± 4.7           19-34 
 
 
26 ± 1.4           24-28 
 
 
Body-mass index (kg/m2) 
 
20.1 ± 2.1        18.5-23.8 
 
 
21.1 ± 1.8        18.5-23.8 
 
 
19.5 ± 1.8            17-22 
 
 
Leptin (ng/ml) 
 
2.70 ± 1.8         1.05-6.7 3.64 ± 1.6          1.69-7.1 
 
 
4.73 ± 2.27           2.3-7.8 
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expressing the CD45RA
+
 and CD45RO
+
 markers, respectively (Figures 1 and 
2). 
 
 
Figure 1 Effects of metreleptin on immune phenotype in terms of absolute number. Absolute 
number of lymphocytes, T, B and natural killer cells in HA subjects over time compared with healthy 
controls. (A, G and H). At baseline, the total populations of lymphocytes, B cells and NK cells were 
significantly lower in HA subjects than in controls (*P < 0.05). (B-F) CD3
+
, CD4
+
, CD8
+
 T, 
CD4
+
CD45RA
+
 and CD4
+
CD45RO
+
 cell population were not different in HA subjects and normal 
controls at baseline. 
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Figure 2. Effects of metreleptin on immune phenotype in terms of  fold change. 36 weeks 
of metreleptin administration in replacement doses induced a statistically significantly  increase 
in terms of  fold change (week of treatment minus baseline) in total lymphocytes, CD3+, 
CD4
+
, CD4
+
CD45RA
+
 naïve  and CD4
+
CD45RO
+
 memory cells (* p < 0.05) (A, B and D-F). 
No significant effect was observed on CD8
+
, B and NK cells (C, G, H). 
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Partial efficacy of metreleptin in restoring T cell proliferation in HA subjects  
We next evaluated the effect of metreleptin treatment on the subjects’ peripheral 
blood mononuclear cell (PBMC) proliferative profile. We stimulated PBMCs  
isolated from subjects’ blood, using either physiologic T-cell specific stimuli (OKT3 
mAb or recall antigen PPD) or using polyclonal unspecific stimuli 
(phytohemagglutinin or phorbol 12-myristate 13-acetate plus ionomycin). We first 
evaluated the impact of HA on in vitro T-cell proliferative responses and found a 
significant reduction in proliferation in HA subjects as compared with normal 
subjects (Fig. 3), particularly in TCR-specific stimulations such as OKT3 
(polyclonal) and PPD (antigen specific) (P < 0.05). Furthermore, using in vitro T-
cell assays, we evaluated the effect of metreleptin treatment in the HA subjects over 
time and observed a significant increase in proliferation at week 36 by OKT3 and 
PPD stimulation (P < 0.05) in metreleptin-treated patients as compared with 
placebo-treated patients (Fig. 4) .  
 
Figure 3. Effects of metreleptin on PBMCs proliferation in terms of cpm. Proliferative 
capacity of PBMCs increased when stimulated with OKT3, phytohemagglutinin (PHA), 
phorbol 12-myristate 13-acetate with ionomicin (PMA/Iono), and purified protein derivative 
(PPD). At baseline the proliferative response to OKT3 and PPD (* p < 0.05) stimulation in HA 
subjects significantly less than in healthy controls (A, D). 
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Figure 4. Effects of metreleptin on PBMCs proliferation in terms of fold change. After 36 
weeks of metreleptin administration in replacement doses, the proliferative response to T-cell-
specific OkT3 (A) and antigen-specific, PPD (D) (* p < 0.05) stimulation was increased in 
metreleptin-treated patients vs. placebo-treated patients in terms of d fold change in 
proliferation over time (calculated as the cpm at week of treatment minus the number cpm at 
baseline T0). This effect was not observed during unspecific stimulations such as PHA (B) and 
PMA/Iono (C). 
 
Immune changes induced by metreleptin are not associated with 
significant changes in serum hormonal patterns, metabolic/inflammatory 
parameters and survival cytokines or metabolic/inflammatory parameters 
We next assessed the impact of metreleptin treatment on hormonal and 
cytokine levels which could be responsible for altered immune cell survival. 
We observed no difference in leptin binding protein (LBP), cortisol, 
adrenocorticotropic hormone (ACTH), and insulin (Figure 5). We also 
investigated the impact of metreleptin treatment on circulating survival 
cytokines such as interleukin (IL)-2, IL-7, IL-15. Again no significant 
difference was detected in the three groups (Figure 5). Finally, no difference 
was observed in the levels of serum metabolic/inflammatory parameters such 
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as CD40L, soluble Tumor Necrosis Factor Receptor (sTNFR1 and sTNFR2 ), 
osteoprotegerin (OPG), monocyte chemoattractant protein-1 (MCP-1), 
myeloperoxidase (MPO), soluble intercellular adhesion molecule-1 (sICAM-
1), resistin, or C-reactive protein (Figure 6).   
 
 
 
Figure 5. Levels of hormones and cytokines. Only leptin levels were significantly higher in 
time curse (A). There were no significant differences in these parameters analysed (B-H). 
 
 
 
 
 
26 
 
 
 
  
Figure 6. Levels of inflammatory and metabolic parameters. There were no significant 
differences in metabolic/inflammatory parameters analysed (A-L). 
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Metreleptin induces production of non-neutralizing anti-leptin antibodies 
with agonistic activity  
Since subcutaneous injections of metreleptin have previously been described  
to induce antibodies we measured anti-metreleptin antibodies over time and 
functionally tested them to assess possible interference with leptin signaling. 
Firstly, we asked whether the antibodies produced after treatment with 
metreleptin in the clinical study were able to affect (either stimulate or 
neutralize) leptin-related proliferation and intracellular signalling. Thus, we 
used the BAF3 cell line after transfection with the long form of the human 
leptin receptor (hLepR
+
BAF3). First, we developed standard curves of anti-
leptin antibodies using an anti-leptin mAb generated in the laboratory (see 
Methods). Antibodies isolated from metreleptin-treated HA subjects were able 
to stimulate proliferation more than leptin alone but only at lower leptin 
concentrations (Figure 7). On the contrary, no additional stimulatory effect was 
observed in the same subjects before treatment, in the placebo-treated subjects, 
or when using IgGs from normal subjects (Figure 7). These functional effects 
were also analyzed at the signalling level by measuring STAT3 
phosphorylation. IgGs from metreleptin-treated HA subjects significantly 
increased p-STAT3 levels (Figure 7), whereas no effect was observed after 
addition of either placebo-treated IgGs or IgGs isolated from normal controls 
(Figure 7). These results suggest that metreleptin treatment results in the 
production of anti-leptin antibodies that are not neutralizing but may 
demonstrate minor agonistic activities on hLepR measured both as increased 
proliferation of a leptin-dependent cell line and as increased hLepR-mediated 
STAT3 signalling. The stimulatory effect of these antibodies is small, however, 
and easily overridden by relatively higher leptin doses. Finally, we also 
evaluated the free leptin levels to assess possible binding of the antibodies and 
found that the free leptin levels increased over time even during production of 
antibodies (Figure 7). 
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Figure 7. Metreleptin treatment induces anti-leptin antibodies with agonistic activity. In 
Panel A (*p < 0.05) is shown the anti-leptin levels in HA subjects treated with leptin and 
placebo, (red and black respectively). Panel B (at week 12, 24, 36 *p < 0.05) shows the free 
leptin in subjects treated with leptin and placebo. In Panels C and D are shown the proliferation 
of the leptin-dependent hLepR+BAF3 cell line in the presence of isolated IgGs from 
metreleptin-treated HA subjects and controls. This assay was performed three times. In Panel E 
is shown STAT3 phosphorylation induced by IgGs from metreleptin-treated HA subjects. One 
representative experiment out of two is shown. 
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Transcriptional signature induced by metreleptin in PBMCs from HA 
subjects 
 
Given the profound effects of metreleptin on immune cell reconstitution and 
proliferation, we next evaluated the modulation of gene expression in PBMCs 
from patients at the different time points during metreleptin treatment (weeks 
12, 24, and 36). When comparing the transcriptional profiles at week 12 of 
treatment vs. baseline (n = 14), we observed 314 differentially expressed genes. 
Of those, 177 were up-regulated, and 137 were down-regulated compared with 
baseline. Likewise, at weeks 24 (n = 16) and 36 (n = 11), only 26 and 79 genes 
changed, respectively, compared with baseline (Fig. 8). Of these, 13 genes 
were up-regulated and 13 were down-regulated at week 24; 50 genes were up-
regulated and 29 were down-regulated at week 36 (Fig. 8). Changes in gene 
expression at week 12 are summarized in Tables 2a and 2b; changes at weeks 
24 and 36 are shown in Tables 3 and 4, respectively. Using the Database for 
Annotation, Visualization and Integrated Discovery (DAVID; National 
Institute of Allergy and Infectious Diseases, National Institutes of Health) 
functional pathway annotation tools, we analyzed the full pathways at weeks 
12, 24, and 36 (dataset table 3,4 and 5 respectively). The genes affected at 
week 12 of treatment included those encoding for proteins involved in the 
regulation (33 genes) and induction (21 genes) of transcription, cell/biological 
adhesion (17 genes), biological proteolytic pathways (ubiquitin conjugation) 
(13 genes), negative regulation of macromolecule metabolic process (17 
genes), vacuole formation (eight genes), and protein (17 genes) and 
macromolecule (20 genes) catabolic process. Among the genes that were 
affected significantly, metreleptin treatment induced the transcripts involved in 
cell survival and development such as the cytokines IL-7 and neurotrophin-3 
(NT-3) factor in PBMCs at week 12. Both IL-7 and NT-3 are involved in 
lymphocyte survival, their effector functions, and neural development ( 51, 52). 
Conversely, genes involved in cell death/apoptosis, such as the B-cell chronic 
lymphocytic leukemia/lymphoma 10 (BCL-10) and TP53-regulator of 
apoptosis-1 (TRIAP-1) genes, were down-modulated significantly, thus 
confirming an antiapoptotic/prosurvival effect of leptin (53-55). The 
transcription factor 7–like-1 (TCF7L1), known to be a transcriptional activator 
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involved in T-lymphocyte differentiation and necessary for survival of CD4
+
 
and CD8
+
 immature thymocytes (56), was up-regulated. In parallel with these 
changes, genes involved in cell adhesion and cell–cell/cell–matrix interactions, 
such as ADAM-metallopeptidase-23 (ADAM-23), actinin-3, vascular adhesion 
molecule-1 (VCAM-1), laminin-α2, and selectin-E (relevant in fertilization, 
muscle development, and neurogenesis), also were up-regulated (57), 
confirming the induction of adhesiveness and activation of immune cells by 
leptin previously observed in vitro (8). Additionally, some hormones important 
in maintaining reproductive functions, such as FSH and progestogen-associated 
endometrial protein (Paep), were up-regulated by metreleptin treatment (3). 
Notably, in addition to its important role in reproductive function, FSH has 
relevant immune-modulating effects (58). These effects suggest that leptin, by 
inducing FSH up-regulation, also could be involved in immunomodulatory 
processes. Moreover, at week 12 we observed up-regulation of genes involved 
in the control of immune tolerance, such as the forkhead box-D3 (FOXD3) 
gene (59), the CD1e molecule [which is necessary for the presentation of lipid 
antigens to T cells (60), and the triggering receptor expressed on myeloid cells-
2 (TREM-2), which may have a role in chronic inflammation and may 
stimulate production inflammatory chemokines and cytokines (61). It is 
interesting that at week 24 (Table 3) the transcription of the aryl-hydrocarbon 
receptor nuclear translocator (ARNT) was up-regulated. ARNT is a key 
component in the elimination of dioxins, well known to be involved in 
autoimmune disease susceptibility, generation of Th17 and regulatory T (Treg) 
cells, and protection from infections (62, 63)The BCL-2–like-11 protein, which 
is an apoptosis facilitator, and the cannabinoid receptor 2 (Cnr2), which is 
known to inhibit macrophage-induced inflammation, were both down-regulated 
(64). Finally, we also observed the down-modulation of the TGF-β receptor-
associated protein-1 (TGFBRAP-1), which plays a role in the TGF-β/activin 
signaling pathways known to be involved in the control of immune responses 
and down-modulation of inflammation. At week 36 (Table 4), we observed up-
regulation of the receptor for the cytotoxic ligand TRAIL, TNF-R-10c. This 
receptor lacks a cytoplasmic death domain and hence is not capable of inducing 
apoptosis; rather, it protects against TRAIL-mediated apoptosis by competing 
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with TRAIL-R1 and -R2 for binding to the ligand. The hormone gastrin also 
was up-regulated, whereas both interleukin enhancer-binding factor-2 (ILF-2) 
and the growth factor-independent 1 (GFI-1) transcription repressor were 
down-regulated (65, 66). The following factors are involved directly and 
indirectly in lymphocyte survival and function: (i) gastrin, in addition to its 
effect on acid secretion by gastric cells, has hematopoietic and 
proinflammatory activities (67); (ii) ILF-2 encodes for a nuclear factor of 
activated T cells (NFAT) required for T-cell expression of the IL-2 gene (68); 
and (iii) GFI-1 encodes a nuclear zinc finger protein that functions as a 
transcriptional repressor (69) GFI-1 plays a role in diverse developmental 
contexts, including hematopoiesis and oncogenesis (69, 70). Finally, the 
significant changes in gene expression seen at week 12 vs. baseline in the 
metreleptin-treated group were validated by real-time PCR (Fig. 9). 
 
 
Figure 8. Transcriptional signature induced by metreleptin in PBMCs from HA subjects. 
Diagram of gene expression profile at week 12, 24 and 36 of treatment with metreleptin versus 
baseline. 17131 were total number of genes that were analyzed; at week 12 there were more 
differentially expressed genes, 308 versus 22 and 74 after 24 and 36 week of treatment, respectively. 
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Table 2a. Upregulated genes in response to metreleptin treatment at week 12 vs baseline. 
 
  
 
 
 
 
 
 
 
 
Table 2b. Downregulated genes in response to metreleptin treatment at week 12 vs baseline. 
Gene symbol Gene assignment Gene ID p-value Fold change 
ADAM23 ADAM metallopeptidase domain 23 8745 0.00657402 0.64445533 
Paep progestagen-associated endometrial protein 5047 0.00268326 0.62717751 
SELE selectin E 6401 0.0076583 0.56464262 
Zfp42 zinc finger protein 42 homolog (mouse) 132625 0.00391605 0.54934091 
Vcam1 vascular cell adhesion molecule 1 7412 0.00908406 0.53175772 
ASB12 ankyrin repeat and SOCS box-containing 12 142689 0.00853215 0.52964533 
Tgm5 transglutaminase 5 9333 0.0037842 0.50489131 
MMP10 matrix metallopeptidase 10 (stromelysin 2) 4319 0.00792751 0.49938345 
FSHB follicle stimulating hormone, beta polypeptide 2488 0.00645861 0.46332061 
NTF3 neurotrophin 3 4908 0.00791533 0.45733451 
CYP1A1 cytochrome P450, family 1, subfamily A, polypeptide 1 1543 0.00851326 0.4530755 
actn3 actn3 89 0.00447152 0.42328933 
TUBGCP4 tubulin, gamma complex associated protein 4 27229 0.00366037 0.42254891 
LRRK1 leucine-rich repeat kinase 1 79705 0.00171516 0.38451621 
TREM2 triggering receptor expressed on myeloid cells 2 54209 0.00797656 0.37922294 
Il7 interleukin 7 3574 0.00912747 0.37264077 
EFEMP1 EGF-containing fibulin-like extracellular matrix protein 1 2202 0.00731755 0.36643077 
ATP2C2 ATPase, Ca++ transporting, type 2C, member 2 9914 0.00339537 0.36473719 
TM4SF4 transmembrane 4 L six family member 4 7104 0.00051904 0.36139 
Lama2 laminin, alpha 2 3908 0.00654983 0.35533335 
TRPM3 transient receptor potential cation channel, subfamily M, member 3 80036 0.00950655 0.33836606 
FUT3 fucosyltransferase 3 (galactoside 3(4)-L-fucosyltransferase, Lewis 
blood group) 
2525 0.00877468 0.32655352 
Apobec1 apolipoprotein B mRNA editing enzyme, catalytic polypeptide 1 339 0.00504257 0.32323031 
tcf7l1 transcription factor 7-like 1 (T-cell specific, HMG-box) 83439 0.00841957 0.31810237 
FOXD3 forkhead box D3 27022 0.00455988 0.31602 
Gpr20 G protein-coupled receptor 20 2843 0.00566617 0.30375888 
Hdac10 histone deacetylase 10 83933 0.00432499 0.28392 
Krt32 keratin 32 3882 0.00276204 0.26272288 
CD1E CD1e molecule 913 0.00678964 0.24852336 
     
Gene 
symbol 
Gene assignment Gene 
ID 
p-value Fold 
change 
CCNI cyclin I 10983 0.00817352 -0.2289351 
TGOLN2 trans-golgi network protein 2 10618 0.00415695 -0.2934237 
Psmd11 proteasome (prosome, macropain) 26S subunit, non-
ATPase, 11 
5717 0.00992041 
 
-0.3663301 
 
Polr2c polymerase (RNA) II (DNA directed) polypeptide C, 
33kDa 
5432 0.00923576 -0.3997785 
Terf2ip telomeric repeat binding factor 2, interacting protein 54386 0.00972071 -0.4122286 
Ergic3 ERGIC and golgi 3 51614 0.00748465 -0.4385879 
NDUFS4 NADH dehydrogenase (ubiquinone) Fe-S protein 4, 
18kDa (NADH-coenzyme Q reductase) 
4724 0.00853818 
 
-0.5093644 
 
TUBA1C tubulin, alpha 1c 84790 0.00458926 -0.5157148 
TRIAP1 TP53 regulated inhibitor of apoptosis 1 51499 0.00476182 -0.5386698 
ARID1B AT rich interactive domain 1B (SWI1-like) 57492 0.00238552 -0.5438516 
Mad2l1bp MAD2L1 binding protein 9587 0.00620568 -0.544755 
LOC10013
3398 
selenoprotein T; similar to Selenoprotein T 51714 0.00627308 -0.5606207 
SNRNP27 small nuclear ribonucleoprotein 27kDa (U4/U6.U5) 11017 0.0028898 -0.6324866 
BCL10 B-cell CLL/lymphoma 10; hypothetical LOC646626 8915 0.0045983 -0.6407714 
arfgap3 ADP-ribosylation factor GTPase activating protein 3 26286 0.00881985 -0.6912068 
Abt1 activator of basal transcription 1 29777 0.00359616 -0.7326123 
rbm38 RNA binding motif protein 38 55544 0.0085592 -0.816973 
TBPL1 TBP-like 1 9519 0.00175630 -0.9431134 
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Table 3. Differences in gene expression profile in response to metreleptin treatment at 
week 24 vs baseline. 
 
 
Table 4. Differences in gene expression profile in response to metreleptin treatment at 
week 36 vs baseline. 
 
 
 
 
 
Gene symbol Gene assignment Gene ID p-value Fold change 
Cacng8 calcium channel, voltage-dependent, gamma 
subunit 8 
59283 0.00197222 
 
0.74792967 
 
ZNF490 zinc finger protein 490 57474 0.00107306 0.59417048 
CENPI centromere protein I 2491 0.00724578 0.45477823 
LELP1 late cornified envelope-like proline-rich 1 149018 0.00013992 0.42264562 
DPPA5 developmental pluripotency associated 5 340168 0.00743253 0.33456177 
ARNT aryl hydrocarbon receptor nuclear 
translocator 
405 0.00860958 0.31569146 
WDR53 WD repeat domain 53 348793 0.00494466 0.29463523 
SPHKAP SPHK1 interactor, AKAP domain containing 80309 0.00351039 0.2461562 
DBT dihydrolipoamide branched chain transacylase 
E2 
1629 0.0099502 
 
0.23485338 
 
BCL2L11 BCL2-like 11 (apoptosis facilitator) 10018 0.00543426 -0.3127599 
PRDM2 PR domain containing 2, with ZNF domain 7799 0.00790638 -0.322973 
Cnr2 cannabinoid receptor 2 (macrophage) 1269 0.00416617 -0.3281563 
TGFBRAP1 transforming growth factor, beta receptor 
associated protein 1 
9392 0.00359646 
 
-0.3439002 
 
ZNF592 zinc finger protein 592 9640 0.00782736 -0.3622582 
MED10 mediator complex subunit 10 84246 0.00406945 -0.547997 
STX10 syntaxin 10 8677 0.00218949 -0.751147 
     
Gene symbol Gene assignment Gene ID p-value Fold change 
TNFRSF10C tumor necrosis factor receptor superfamily, 
member 10c, decoy without an intracellular 
domain 
8794 0.006717 
 
0.90305714 
 
ZNF200 zinc finger protein 200 7752 0.00610212 0.54233656 
f2rl1 coagulation factor II (thrombin) receptor-like 1 2150 0.00829106 0.51888316 
GAST gastrin 2520 0.00128913 0.46499107 
GLI1 GLI family zinc finger 1 2735 0.00939256 0.45136181 
CYTH4 cytohesin 4 27128 0.00437337 0.36625752 
bbs7 Bardet-Biedl syndrome 7 55212 0.00857128 0.27351589 
ilf2 interleukin enhancer binding factor 2, 45kDa 3608 0.00451506 -0.692222 
TXNIP thioredoxin interacting protein 10628 0.00791743 -0.4120624 
Cdk5r1 cyclin-dependent kinase 5, regulatory subunit 1 
(p35) 
8851 0.00957235 
 
-0.4554088 
 
GFI1 growth factor independent 1 transcription 
repressor 
2672 0.0062539 
 
-0.5224277 
 
ZBTB16 zinc finger and BTB domain containing 16 7704 0.00228704 -0.7820146 
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Table 5. Sequences of primers for RT-PCR microarray validation. 
 
 
 
Figure 9. Gene-expression levels were verified by real-time PCR. Metreleptin-treated groups 
at week 12 were compared with the baseline levels. Gene-expression levels of IL-7 (B), 
selectin E (C), and Ergic3 (E) were changed significantly (*P ≤ 0.05) compared with their 
baseline levels. Gene-expression levels of ADAM-23 (A), BCL-10 (D), and TRIAP-1 (F) did 
not change significantly from baseline 
Gene name forward reverse 
18s GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG 
ADAM23 GCTACAATGGCGAGTGCAAG CTCCATCCTTCCCGCAGTTT 
SELE GTGAAGCTCCCACTGAGTCC AGCCAGAGGAGAAATGGTGC 
IL7 TTTATTCCGTGCTGCTCGC CCAGGGCAGCTGGTTTTCTT 
Ergic3 GAAGTCAATAAGGTGGCCGGA AGCTCTGCAAGTCATGGATCT 
TRIAP1 CTGTCGCCATGAACAGTGTG AAATTTCTCGGCGAACCAGC 
BCL10 TTCCAGATGGAGCCACGAAC CGTCGTGCTGGATTCTCCTT 
Gene name forward reverse 
18s GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG 
ADAM23 GCTACAATGGCGAGTGCAAG CTCCATCCTTCCCGCAGTTT 
SELE GTGAAGCTCCCACTGAGTCC AGCCAGAGGAGAAATGGTGC 
IL7 TTTATTCCGTGCTGCTCGC CCAGGGCAGCTGGTTTTCTT 
Ergic3 GAAGTCAATAAGGTGGCCGGA AGCTCTGCAAGTCATGGATCT 
TRIAP1 CTGTCGCCATGAACAGTGTG AAATTTCTCGGCGAACCAGC 
BCL10 TTCCAGATGGAGCCACGAAC CGTCGTGCTGGATTCTCCTT 
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Acute in vivo metreleptin signaling in PBMCs and in vitro signaling on 
CD4
+
 T cells from lean, normoleptinemic subjects 
We next investigated the effects of acute in vivo metreleptin administration on 
signaling in both PBMCs and CD4
+
 T cells from lean subjects. Similar to the 
transcriptional signature induced by metreleptin in PBMCs taken from subjects 
with HA, the signaling pathways involved in cell growth/survival/proliferation, 
such as the STAT3, AMPK, mTOR, ERK1/2, and Akt pathways, were 
activated directly by acute in vivo metreleptin administration in PBMCs (Fig. 
10 A–F) and by acute in vitro stimulation with metreleptin in isolated CD4+ T 
cells from lean subjects (Fig. 10 G–L). In contrast, acute in vivo metreleptin 
administration did not regulate SHP2 activation either in PBMCs or in isolated 
CD4
+
 T cells, probably because induction of LepR signaling without 
simultaneous TCR engagement cannot induce high counterregulatory loops 
mediated by SHP2. 
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Figure 10.  Acute in vivo metreleptin-induced signaling in PBMCs and in vitro in CD4
+
 T 
cells from lean normoleptinemic subjects. In panels A-F, are shown western blotting 
analyses on PBMCs from lean females upon in vivo metreleptin stimulation. In panels G-L, are 
shown the same analyses performed on isolated highly purified CD4
+
 T cells stimulated in 
vitro with metreleptin at 1h. Both PBMCs in vivo and isolated CD4
+
 T cells in vitro provided 
similar results. All data were analyzed using student t-test. Values are means (n=3) ± SD.  
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Discussion 
Prior evidence suggests that a link exixts between energy status and immunity 
as well as metabolic and neuroendocrine functions has been proposed (71). The 
adipocyte-derived hormone leptin has been suggested as one of the key players 
in this process. Indeed, leptin represents for the brain a signal of the amount of 
energy stored in fat and/or acute changes in energy availability and, similarly, 
it has been proposed that leptin is the signal conveying to the immune cells 
information on energy availability (7). While extensive experimental evidence 
has suggested a link between circulating leptin level and immune 
function/homeostasis in leptin deficient mice and humans, still little is known 
about the capacity of leptin to affect immune homeostasis in normal 
individuals and in conditions of relative leptin deficiency in humans. With this 
study we provide evidence that in an experimental setting where HA women 
served as subjects with chronic acquired relative leptin deficiency there is a 
reduction in T cells particularly in the CD4
+
 T cell subset and in their 
proliferative capacity. Administration of metreleptin in replacement doses 
restored the number of CD4
+
 T cells and partially their proliferative potential. 
This study demonstrates for the first time, in a placebo controlled, randomized 
manner, that relative leptin deficiency is associated with reduced number and 
function of T cells in humans and that metreleptin treatment restores immune 
cell population (specifically CD4
+
 T cell) size and function. An important 
difference, also reaching statistical significance, was observed particularly in 
the capacity of metreleptin to increase CD4
+ 
T cell numbers thus helping the 
immune-reconstitution process in HA subjects. This novel aspect of 
metreleptin as an immune-reconstituting agent could have great impact in 
settings in which CD4
+
 T cells are reduced, such as in states of chronic energy 
deficiency including cachexia associated with tuberculosis (TB), HIV infection 
or exposure to radiation etc (72, 73). In the context of immune reconstitution of 
the CD4+ T-cell compartment, the results obtained are highly encouraging. 
Indeed, the normal range of CD4+ T cells in adult humans generally varies 
from 750-1,200 cells/mm
3
 (74). In placebo-treated HA subjects we observed a 
trend from low degree lymphopenia to frank lymphopenia over time:  basal 
average CD4
+
 T-cell count of these subjects was 721 ± 363 cells/mm
3
; this cell 
 
38 
 
count became 428 ± 176 cells/mm
3
 at week 36. This progressive decline in the 
CD4
+
 T-cell count was significant and resembled the decline in CD4
+
 T counts 
seen in the progression of other immunocompromised conditions, such as HIV 
infection. Although the two study groups (placebo and metreleptin) had similar 
basal CD4
+
 T-cell counts (721 ± 363 and 775 ± 234 CD4
+
 T cells/mm
3
, 
respectively), metreleptin treatment was able to increase subjects’ CD4+ cell 
count from 775 ± 234 at baseline to 1,152 ± 227 cells/mm
3
 at week 36; the 
effect of metreleptin treatment on CD4
+
 T-cells was even more apparent when 
we compared the CD4
+
 T-cell counts of placebo-treated vs. metreleptin-treated 
subjects at week 36 (428 ± 176 cells for placebo-treated subjects vs. 1,152 ± 
227 cells/mm
3
 for metreleptin-treated subjects).  At the transcriptional level, a 
specific gene signature was observed for the first time in PBMCs from 
metreleptin treated subjects where genes involved in cell survival, hormonal 
response and adhesion were upregulated and those involved in cell 
death/apoptosis were down-regulated. These observations confirm that leptin 
administration promotes the expression of genes involved in pathways critical 
to cell survival, proliferation, and migration through transcriptional regulation 
(8, 75). These observations also help explain leptin’s marked ability to improve 
CD4
+
 T-cell survival and to promote immune reconstitution, perhaps 
suggesting an important role for leptin in the context of susceptibility to 
autoimmune disease (1). We and others have recently shown that leptin 
administration is effective in improving the metabolic profile in subjects with 
HAART associated lipodystrophy (76-79). Also, metreleptin therapy could be 
considered in other disease states where CD4 T cells play a role such as in the 
treatment of the most common form of intestinal infection leading to diarrhea 
in less developed countries: amebiasis (80). Indeed, it has been recently 
demonstrated in observational studies that a specific LepR polymorphism 
appears to be able to impair leptin signaling and induce higher susceptibility to 
this parasite (21). We also report herein that we detected anti-metreleptin 
antibodies in the serum of metreleptin treated HA subjects (3). This finding is 
not surprising since subcutaneous injections of native proteins can activate 
immune responses. Also considering the double nature of leptin, as a probable 
antigenic protein and an immunostimulating agent, it cannot be excluded that 
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leptin could simultaneously act both subcutaneously as an antibody generating 
protein and peripherally as a pro-inflammatory agent, allowing thus easier 
production of antibodies. In spite of this, we found that the antibodies produced 
may bind endogenous leptin but without having any effects in neutralizing its 
signaling capacity. Since leptin acts in a pleiotropic manner at multiple levels, 
it cannot be excluded that immune reconstituting activities observed in HA 
subjects could be a result of leptin’s action on stress hormones or circulating 
cytokines which control survival of T cells and not necessarily to the direct 
action of leptin on CD4 T cells. To rule out these actions we evaluated in the 
serum pro-survival cytokines such as IL-2, IL-7 and IL-15 all involved in T 
cell survival and thymic selection, and observed no significant change in levels 
during metreleptin treatment (51). In contrast, IL-7 gene transcript was found 
to be up-regulated in PBMCs from treated HA patients, thus suggesting that 
metreleptin treatment was able to induce selectively, not systemically, the pro-
survival cytokine IL-7 in immune cells. In addition, the transcript of the FSH 
hormone was increased at the immune cell level; since FSH is important to 
promote immune cell homeostasis and inflammatory responses we cannot 
exclude that some of the peripheral immune-cell improvements could be also 
ascribed to increased FSH (81). Also stress hormones such as cortisol, ACTH, 
and other hormones like insulin did not correlate significantly with changes in 
immune function reported herein. Therefore, we hypothesize that leptin’s 
immune reconstituting actions are partly to be ascribed to an indirect pro-
survival action on T cells (via induction of IL-7 and FSH) but also to a direct 
action on the LepR known to be expressed on T cells. Nonetheless, we recently 
demonstrated that HA subjects treated with metreleptin recovered menstruation 
and regained normal levels of hormones in the gonadal, thyroid, growth 
hormone, and adrenal axes (82). We also demonstrated changes in markers of 
bone metabolism suggestive of bone formation (3, 82) and, in the open label 
follow up period, we did detect a change in lumbar spine bone mineral density 
after treatment of leptin for two years (82). Therefore, the improvement in 
immune cell number and function could be related, in part, to the normalization 
of the gonadal axis (3, 82), evidence which is also corroborated by the 
increased FSH transcript also in immune cells. Finally, studies from the Tschöp 
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group have shown that leptin-initiated neuroendocrine pathways are able to 
functionally coordinate the systemic immune response (83). More specifically 
they observed that leptin deficiency was associated with an impaired immune 
response and lowered survival in a murine model of sepsis, mainly due to 
impaired neutrophil function. On the contrary, genetic rescue of leptin 
signalling exclusively and specifically within the central nervous system (CNS) 
was sufficient to improve mortality and cytokine profiles in sepsis, suggesting 
that leptin-dependent neurocircuitry in the CNS is required for efficient 
coordination of the immune response in sepsis to limit organ damage and 
prevent mortality. All the observations presented herein reveal the existence of 
a specific CNS leptin-signalling system that controls systemic immune defense 
in a functionally relevant manner. It is possible to speculate that leptin might 
act in the brain to directly regulate peripheral immune function and thereby 
contribute to better outcomes in different infectious diseases compared with 
states of relative or total leptin deficiency. Therefore, it is possible that the 
effects observed in HA women could also be ascribed to a specific CNS 
activity whereby metreleptin partly restores immune functions in the periphery 
(83). Finally, we extended these studies by performing acute in vivo leptin 
signaling experiments to determine whether pathways induced by metreleptin 
in PBMCs from lean subjects are similar or different from those induced by 
metreleptin in PBMCs from HA subjects. Consistent with data obtained in 
PBMCs from HA subjects, in which acute in vivo metreleptin administration 
activates signaling pathways involved in cell growth/survival/proliferation (i.e., 
STAT3, AMPK, ERK1/2, mTOR, and Akt), we replicated these results in 
highly purified CD4
+
 T cells from lean subjects using an in vitro method. 
Although we have not examined all signaling pathways potentially mediating 
leptin’s actions on PBMCs in vivo, we have studied signaling pathways that we 
believe are of critical importance. The results potentially are biologically 
important. The mechanisms reported herein lend themselves to future studies 
with an ultimate goal of identifying in vivo leptin signaling in immune cells 
and states in which leptin replacement could help the immune-reconstitution 
process. In conclusion, this study adds novel data on the capacity of 
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metreleptin treatment to facilitate immune reconstitution in non-obese subjects 
with acquired hypoleptinemia such as HA.  
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Conclusions 
This is the first randomized, placebo-controlled trial of metreleptin 
administration in humans over a period of 36 weeks. Our data can have 
relevance in hypoleptinemic states of negative energy balance, such as 
recurrent infections associated with reduced T cell counts, immunodeficiencies 
such as HIV and Tuberculosis very frequently associated with low body weight 
and adipocyte mass. This study adds significant new information to the 
understanding of the biology of CD4
+
 T cells in the context of hypoleptinaemia 
and how their function can be regulated by the metabolic state through leptin. 
Moreover, considering that nutritional deprivation or chronic restriction reduce 
autoimmune diseases onset, manipulation of the leptin axis, and in general of 
nutritional status, might represent a new means to modulate T cell tolerance in 
infections and autoimmunity. Thus, the effects we observed herein need to be 
replicated in larger studies and in different disease states associated with 
chronic hypoleptinemia, and it is necessary to study whether metreleptin 
administration could therefore contribute to improved morbidity and mortality 
in these conditions remains to be shown in future studies. 
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